About the API
Neratinib, the active ingredient in neratinib maleate, belongs to the class of molecules termed antineoplastic agents, which inhibit the maturation, growth or spread of tumor cells. It significantly reduces the risk of recurrence of breast cancer in post-surgery adult patients who have been treated with trastuzumab (herceptin) for early stage HER2-overexpressed breast cancer. In clinical studies, patients taking Neratinib showed a 33% reduction in the risk of recurrence within two years.
Orally administered, neratinib is currently under investigation for use in many other forms of cancer, including metastatic breast cancer, colorectal cancer and lung cancer. A clinical trial demonstrated that neratinib and temsirolimus in combination produced responses in some patients with HER2-mutant lung cancers.